Adlai Nortye Ltd.
ANLAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 10, 2026 | Jefferies | Maury Raycroft | $31.00(+111%) | $14.70 | StreetInsider |
| Sep 8, 2026 | Loop Capital Markets | Dev Prasad | $49.00(+226%) | $15.01 | StreetInsider |
| May 28, 2026 | Oppenheimer | $32.00(+191%) | $11.00 | TheFly | |
| Apr 20, 2026 | H.C. Wainwright | Joseph Pantginis | $20.00(+25%) | $16.01 | TheFly |
| Feb 13, 2026 | H.C. Wainwright | $16.00(+66%) | $9.65 | TheFly | |
| Sep 4, 2024 | H.C. Wainwright | Joseph Pantginis | $9.00(+232%) | $2.71 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | Apr 20, 2026 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Feb 13, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 2, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 11, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 18, 2024 |
Earnings History
Next report: Mar 3, 2027 · EPS est. $-0.15| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-0.04 | $-0.06 | $14.7M | $9.6M |
| Apr 10, 2026 | $-0.81 | $-0.18 | $2.5M | $450.3K |
| Dec 29, 2025 | $-0.18 | $-0.18 | — | $313.2K |
| Aug 7, 2025 | $-0.18 | $-0.18 | — | — |
| Apr 30, 2025 | $-0.22 | $-0.53 | — | — |
| Feb 26, 2025 | $-0.22 | $-0.53 | — | — |
| Aug 8, 2024 | $-0.35 | $-1.06 | $745.0K | $745.0K |
| Apr 20, 2024 | $-1.59 | $-0.38 | $745.0K | — |
News
AN4035 late-breaking abstract selected for an oral presentation at the upcoming ENA Symposium in Barcelona Oral presentation will include translational and EGFR combination data for first-in-class AN4035 AN4035 is a novel CEACAM5-targeting ADC armed with a proprietary pan-RAS(ON) inhibitor payload, designed to broaden the therapeutic window SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd.
AN4035, a first-in-class investigational pan-RAS(ON) inhibitor-based ADC, will be evaluated as monotherapy and in combination with cetuximab in the ongoing global Phase I trial
Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.
SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd. (NASDAQ: ANL) (“Adlai Nortye” or the “Company”), a clinical-stage biotechnology company focused on the development of innovative cancer therapies, today announced the appointment of Christopher Liu, PharmD, as Head of Investor Relations and Public Relations. Dr. Liu brings nearly a decade of equity research experience, with a focus on biotechnology and oncology.
Shares of Adlai Nortye Ltd. Sponsored ADR (NASDAQ: ANL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-May-Proceed" letter SINGAPORE and NORTH BRUNSWICK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Group Ltd.
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed to Scientific Advisory Board SINGAPORE and NORTH BRUNSWICK, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd.